KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing ...

Cingulate (CING) announced that the positive Phase 3 results from its pivotal trial of CTx-1301 in pediatric ADHD, were recently presented by Ann Childress, M.D., at the AACAP Annual Meeting in ...

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products ...

CINGW Company Profile Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder ...

A new study shows that autism symptom severity, rather than a formal diagnosis, aligns with shared brain-connectivity patterns across children diagnosed with autism or ADHD.

The phrenic nerve controls the diaphragm, the dome-shaped muscle that is primarily responsible for breathing. Contraction of the diaphragm expands the lungs and draws air into them. The phrenic nerve ...

In 2025, the Muhammad Ali Center published a report on compassion in the United States that revealed that 61 percent of the more than 5,000 people surveyed between 2020 and 2024 said they perceived a ...